Abscess formation and alpha-hemolysin induced toxicity in a mouse model of Staphylococcus aureus peritoneal infection

Infection and Immunity

Volumn 80, Issue 10, 2012, Pages 3721-3732

  Rauch, Sabine ^a   DeDent, Andrea C ^a   Kim, Hwan Keun ^a   Wardenburg, Juliane Bubeck ^a   Missiakas, Dominique M ^a   Schneewind, Olaf ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HEMOLYSIN; COLLAGEN; FIBRIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 7B8; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOPSY; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FIBRIN DEPOSITION; HISTOPATHOLOGY; INOCULATION; KIDNEY ABSCESS; KIDNEY FAILURE; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PERITONITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROPERITONEAL ABSCESS; STAPHYLOCOCCUS INFECTION;

ABSCESS; ANIMALS; ANTIBODIES, NEUTRALIZING; BACTERIAL TOXINS; COLLAGEN; DISEASE MODELS, ANIMAL; FEMALE; FIBRIN; HEMOLYSIN PROTEINS; KIDNEY DISEASES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PERITONITIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 84867595628     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00442-12     Document Type: Article

References (55)

1. Baba T, Bae T, Schneewind O, Takeuchi F, Hiramatsu K. 2007. Genome sequence of Staphylococcus aureus strain Newman and comparative analysis of staphylococcal genomes. J. Bacteriol. 190:300-310.
2. Bae T, et al. 2004. Staphylococcus aureus virulence genes identified by bursa aurealis mutagenesis and nematode killing. Proc. Natl. Acad. Sci. U. S. A. 101:12312-12317.
3. Bagdasarian N, Heung M, Malani PN. 2012. Infectious complications of dialysis access devices. Infect. Dis. Clin. N. Am. 26:127-141.
4. Bernheimer AW. 1965. Staphylococcal alpha toxin. Ann. N. Y. Acad. Sci. 128:112-123.
5. Bubeck-Wardenburg J, Patel R, Schneewind O. 2007. Surface proteins and exotoxins are required for the pathogenesis of Staphylococcus aureus pneumonia. Infect. Immun. 74:1040 -1044.
6. Bubeck-Wardenburg J, Bae T, Otto M, DeLeo FR, Schneewind O. 2007. Poring over pores: α-hemolysin and Panton-Valentine leukocidin in Staphylococcus aureus pneumonia. Nat. Med. 13:1405-1406.
7. Bubeck-Wardenburg J, Missiakas DM, Schneewind O. 2010. Vaccines for Staphylococcus aureus infections, p 728-736. In Levine MM, et al (ed), New generation vaccines, 4th ed. Informa Health Care, Washington, DC.
8. Bubeck-Wardenburg J, Palazzolo-Ballance AM, Otto M, Schneewind O, DeLeo FR. 2008. Panton-Valentine leukocidin is not a virulence determinant in murine models of community-associated methicillin-resistant Staphylococcus aureus disease. J. Infect. Dis. 198:1166-1170.
9. Bubeck-Wardenburg J, Schneewind O. 2008. Vaccine protection against Staphylococcus aureus pneumonia. J. Exp. Med. 205:287-294.
10. Bunce C, Wheeler L, Reed G, Musser J, Barg N. 1992. Murine model of cutaneous infection with gram-positive cocci. Infect. Immun. 60:2636-2640.
11. Cheng AG, et al. 2009. Genetic requirements for Staphylococcus aureus abscess formation and persistence in host tissues. FASEB J. 23:3393-3404.
12. Cheng AG, et al. 2010. Contribution of coagulases toward Staphylococcus aureus disease and protective immunity. PLoS Pathog. 6:e1001036. doi: 10.1371/journal.ppat.1001036.
13. Cohn ZA. 1962. Determinants of infection in the peritoneal cavity. I. Response to and fate of Staphylococcus aureus and Staphylococcus albus in the mouse. Yale J. Biol. Med. 35:12-28.
14. Cohn ZA. 1962. Determinants of infection in the peritoneal cavity. II. Factors influencing the fate of Staphylococcus aureus in the mouse. Yale J. Biol. Med. 35:29-47.
15. DeDent A, Kim HK, Missiakas DM, Schneewind O. 2012. Exploring Staphylococcus aureus pathways to disease for vaccine development. Semin. Immunopathol. 34:317-333.
16. DeLeo FR, Chambers HF. 2009. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat. Rev. Microbiol. 7:629-641.
17. DeLeo FR, et al. 2011. Molecular differentiation of historic phage-type 80/81 and contemporary epidemic Staphylococcus aureus. Proc. Natl. Acad. Sci. U. S. A. 108:18091-18096.
18. Diep BA, et al. 2006. Complete genome sequence of USA300, an epidemic clone of community-acquired methicillin-resistant Staphylococcus aureus. Lancet 367:731-739.
19. Duthie ES, Lorenz LL. 1952. Staphylococcal coagulase: mode of action and antigenicity. J. Gen. Microbiol. 6:95-107.
20. Fattom AI, Sarwar J, Ortiz A, Naso R. 1996. A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge. Infect. Immun. 64:1659-1665.
21. Gillet Y, et al. 2002. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 359:753-759.
22. Glowacki LS, et al. 1994. Surveillance and prophylactic intervention of Staphylococcus aureus nasal colonization in a hemodialysis unit. Am. J. Nephrol. 14:9 -13.
23. Holley JL, Bernardini J, Piraino B. 1994. Infecting organisms in continuous ambulatory peritoneal dialysis patients on the Y-set. Am. J. Kidney Dis. 23:569 -573.
24. Inoshima I, et al. 2011. A Staphylococcus aureus pore-forming toxin subverts the activity of ADAM10 to cause lethal infection in mice. Nat. Med. 17:1310 -1314.
25. Kapral FA. 1965. Factors involved in experimental staphylococcal peritonitis. Ann. N. Y. Acad. Sci. 128:259 -273.
26. Kennedy AD, et al. 2010. Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J. Infect. Dis. 202:1050 -1058.
27. Kernodle DS, Voladri RK, Menzies BE, Hager CC, Edwards KM. 1997. Expression of an antisense hla fragment in Staphylococcus aureus reduces alpha-toxin production in vitro and attenuates lethal activity in a murine model. Infect. Immun. 65:179 -184.
28. Kim HK, Cheng AG, Kim H-Y, Missiakas DM, Schneewind O. 2010. Non-toxigenic protein A vaccine for methicillin-resistant Staphylococcus aureus infections. J. Exp. Med. 207:1863-1870.
29. Kim HK, et al. 2010. IsdA and IsdB antibodies protect mice against Staphylococcus aureus abscess formation and lethal challenge. Vaccine 28: 6382-6392.
30. Klarenbach S, Manns B. 2009. Economic evaluation of dialysis therapies. Semin. Nephrol. 29:524-532.
31. Klevens RM, Edwards JR, Gaynes RP, System NNIS. 2008. The impact of antimicrobial-resistant, health care-associated infections on mortality in the United States. Clin. Infect. Dis. 47:927-930.
32. Klevens RM, et al. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771.
33. Koenig MG. 1962. Factors relating to the virulence of staphylococci. I. Comparative studies on two colonial variants. Yale J. Biol. Med. 34:537-559.
34. Koenig MG, Melly MA, Rogers DE. 1962. Factors relating to the viru-lence of staphylococci. II. Observations on four mouse-pathogenic strains. J. Exp. Med. 116:589 -599.
35. Liu C, et al. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin. Infect. Dis. 52:285-292.
36. Lowy FD. 1998. Staphylococcus aureus infections. N. Engl. J. Med. 339: 520-532.
37. Luzar MA, et al. 1990. Staphylococcus aureus nasal carriage and infection in patients on continuous ambulatory peritoneal dialysis. N. Engl. J. Med. 322:505-509.
38. Mazmanian SK, Liu G, Ton-That H, Schneewind O. 1999. Staphylococcus aureus sortase, an enzyme that anchors surface proteins to the cell wall. Science 285:760 -763.
39. McAdow M, et al. 2011. Preventing Staphylococcus aureus sepsis through the inhibition of its agglutination in blood. PLoS Pathog. 7:e1002307. doi:10.1371/journal.ppat.1002307.
40. McKenney D, et al. 1999. Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science 284:1523-1527.
41. Menzies BE, Kernodle DS. 1996. Passive immunization with antiserum to a nontoxic alpha-toxin mutant from Staphylococcus aureus is protective in a murine model. Infect. Immun. 64:1839 -1841.
42. Menzies BE, Kernodle DS. 1994. Site-directed mutagenesis of the alphatoxin gene of Staphylococcus aureus: role of histidines in toxin activity in vitro and in a murine model. Infect. Immun. 62:1843-1847.
43. Novick RP, Jiang D. 2003. The staphylococcal saeRS system coordinates environmental signals with agr quorum sensing. Microbiology 149:2709-2717.
44. Panizzi P, et al. 2011. In vivo detection of Staphylococcus aureus endocarditis by targeting pathogen-specific prothrombin activation. Nat. Med. 17:1142-1146.
45. Peacock SJ, de Silva I, Lowy FD. 2001. What determines nasal carriage of Staphylococcus aureus? Trends Microbiol. 9:605- 610.
46. Peacock SJ, et al. 2000. Outcome following staphylococcal peritonitis. Perit. Dial. Int. 20:215-219.
47. Powers ME, Kim HK, Wang Y-T, Bubeck-Wardenburg J. 2012. ADAM10 mediates vascular injury induced by Staphylococcus aureus α-hemolysin. J. Infect. Dis. [Epub ahead of print.] doi:10.1093/infdis/jis192.
48. Ragle BE, Bubeck-Wardenburg J. 2009. Anti-alpha-hemolysin monoclonal antibodies mediate protection against Staphylococcus aureus pneumonia. Infect. Immun. 77:2712-2718.
49. Rubin J, et al. 1980. Peritonitis during continuous ambulatory peritoneal dialysis. Ann. Intern. Med. 92:7-13.
50. Stranger-Jones YK, Bae T, Schneewind O. 2006. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc. Natl. Acad. Sci. U. S. A. 103:16942-16947.
51. Troidle L, Finkelstein F. 2006. Treatment and outcome of CPDassociated peritonitis. Ann. Clin. Microbiol. Antimicrob. 5:6 -13.
52. Voyich JM, et al. 2006. Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? J. Infect. Dis. 194:1761-1770.
53. Wilke GA, Bubeck-Wardenburg J. 2010. Role of a disintegrin and metalloprotease 10 in Staphylococcus aureus alpha-hemolysin-mediated cellular injury. Proc. Natl. Acad. Sci. U. S. A. 107:13473-13478.
54. Yu VL, et al. 1986. Staphylococcus aureus nasal carriage and infection in patients on hemodialysis. N. Engl. J. Med. 315:91-96.
55. Zimakoff J, et al. 1996. Staphylococcus aureus carriage and infections among patients in four haemo- and peritoneal-dialysis centres in Denmark. J. Hosp. Infect. 33:289 -300.